**Curriculum Vitae**

Name: Jamal Mohamed Barani د جمال محمد براني

Date and place of birth: 22.08.1964 Misurata-Libya

Marital status: Married with three children

Languages: Arabic as mother language, English and Swedish

Address of work: Misurata Cancer Center-Cardiology Unit

E-mail: jamal.barani1964@gmail.com

**Professional qualifications**

 -M.B.CH.B Arab medical university 1990

-Swedish Board in Cardiology 2000

-Swedish Board in Medicine 2005

- PhD in peripheral arterial disease 2006

**Work experience:**

-March 1991-Dec 1995 As SHO in internal medicine at Misurata Central Hospital

-Jan 1996-2000 specialist training in Cardiology, University Hospital, Malmö, Helsingborg and Lund-Sweden

-As specialist Doctor and PhD researcher at Angiology Department—Malmö university Hospital 2001-2007-Sweden

-As Consultant Doctor (Cardiologist) March 2008-Dec 2012 at Landskrona Hospital- Sweden

-Jan 2013-present, as Consultant Cardiologist-cardiology unit at Misurata Cancer Center.

-Present member of teaching staff at Misurata University- Faculty of Medicine

**Academic experience, research and publication**

1 - Cardiac function, inflammatory mediators and mortality in critical limb ischemia

Barani J, Mattiasson I, Lindblad B, Gottsäter A.

Angiology. 2006 Aug-Sep; 57(4):437-44

2- Inflammatory mediators are associated with 1-year mortality in critical limb ischemia

Barani J, Nilsson J, Mattiasson I, Lindblad B, Gottsäter A. J Vasc Surg. 2005 Jul;42(1):75-80

3- Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia.

Barani J, Mattiasson I, Lindblad B, Gottsäter A.

Int Angiol. 2005 Mar; 24(1):59-63.

4- Platelet and leukocyte activation during aortoiliac angiography and angioplasty.

Barani J, Gottsäter A, Mattiasson I, Lindblad B.

Eur J Vasc Endovasc Surg. 2002 Mar; 23(3):220-5

5- Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischemia?

Bertz L, Barani J, Gottsäter A, Nilsson PM, Mattiasson I, Lindblad B.

Int Angiol. 2006 Dec; 25(4):370-7

6- Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia.

Isma N, Barani J, Mattiasson I, Lindblad B, Gottsäter A.

Angiology. 2008 Oct-Nov; 59(5):542-8

**Scientific abstracts:**

Barani J, Mattiasson I, Lindblad B, Gottsätter A. Critical Limb ischemia-Incidence, co-mortality and risk factors for atherosclerosis, Int. Angiol 2003;22:3(Suppl.1)97

Barani J, Gottsätter A, Lindblad B, Mattiasson I High prevalence of treatable medical risk factors in patients with critical limb ischemia. Hygie 2003; 112:197

Gottsätter A, Barani J, Lindblad B, Mattiasson I, Plasma levels of tumor Necrosis factor α and Neoptrin are independent predictor of mortality in Critical Limb Ischemia. Abstract in Swedish medical association national assembly 2004

Barani J, Gottsätter A, Lindblad B, Mattiasson I, Heart function and inflammatory markers in critical limb ischemia, Abstract at the Swedish medical association national assembly

Gottsätter A, Barani J, Lindblad B, Mattiasson I, Plasma levels of tumor Necrosis factor α and Neoptrin are independent predictor ofmortality in Critical Limb Ischemia. Circulation 2004; 110 suppl. III

**Conferences**:

Yearly attendance of ESC (European society of

Cardiology) conferences during stay in Sweden